Cargando…

Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia

INTRODUCTION: Previously, controlled trials have demonstrated the efficacy and tolerability of fixed doses of incobotulinumtoxinA (Xeomin, NT 201, botulinum toxin type A free from complexing proteins) to treat cervical dystonia (CD). To explore the clinical relevance of these findings, this study ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dressler, Dirk, Paus, Sebastian, Seitzinger, Andrea, Gebhardt, Bernd, Kupsch, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2013
Materias:	Movement Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756428/ https://www.ncbi.nlm.nih.gov/pubmed/23687362 http://dx.doi.org/10.1136/jnnp-2012-303608

Ejemplares similares

Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin(®))
por: Dressler, Dirk, et al.
Publicado: (2013)

Selective peripheral denervation for cervical dystonia: long-term follow-up
por: Bergenheim, A Tommy, et al.
Publicado: (2015)

A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia
por: Evidente, Virgilio Gerald H., et al.
Publicado: (2013)

Pain Reduction in Cervical Dystonia Following Treatment with IncobotulinumtoxinA: A Pooled Analysis
por: Albanese, Alberto, et al.
Publicado: (2023)

Pathogenesis of dystonia: is it of cerebellar or basal ganglia origin?
por: Kaji, Ryuji, et al.
Publicado: (2018)

Psychiatric associations of adult-onset focal dystonia phenotypes
por: Berman, Brian D, et al.
Publicado: (2017)

Rest and other types of tremor in adult-onset primary dystonia
por: Erro, Roberto, et al.
Publicado: (2014)

Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia
por: Fernandez, Hubert H., et al.
Publicado: (2013)

Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study
por: Berman, Brian D, et al.
Publicado: (2020)

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm
por: Truong, Daniel D., et al.
Publicado: (2013)

Structural magnetic resonance imaging in dystonia: A systematic review of methodological approaches and findings
por: MacIver, Claire L., et al.
Publicado: (2022)

Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia
por: Fernandez, Hubert H., et al.
Publicado: (2013)

Effect of subthalamic nucleus deep brain stimulation on dual-task cognitive and motor performance in isolated dystonia
por: Mills, Kelly A, et al.
Publicado: (2015)

Differences in globus pallidus neuronal firing rates and patterns relate to different disease biology in children with dystonia
por: McClelland, V M, et al.
Publicado: (2016)

Adult‐onset idiopathic dystonia: A national data‐linkage study to determine epidemiological, social deprivation, and mortality characteristics
por: Bailey, Grace A., et al.
Publicado: (2021)

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia
por: Fernandez, Hubert H, et al.
Publicado: (2019)

Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II
por: Kent, Ruth, et al.
Publicado: (2021)

Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA
por: Fheodoroff, Klemens, et al.
Publicado: (2020)

The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease
por: Barker, Roger A, et al.
Publicado: (2013)

Profile of Xeomin(®) (incobotulinumtoxinA) for the treatment of blepharospasm
por: Park, Juwan, et al.
Publicado: (2011)

Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study
por: Wissel, Jörg, et al.
Publicado: (2017)

Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm
por: Fernandez, Hubert H., et al.
Publicado: (2014)

Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
por: Santamato, Andrea
Publicado: (2016)

Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults
por: Jost, Wolfgang H., et al.
Publicado: (2023)

Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques
por: Nikolis, Andreas, et al.
Publicado: (2018)

Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins
por: Hefter, Harald, et al.
Publicado: (2021)

IncobotulinumtoxinA Injection for Treating Children with Idiopathic Toe Walking: A Retrospective Efficacy and Safety Study
por: Filippetti, Mirko, et al.
Publicado: (2022)

Long-term efficacy and safety of incobotulinumtoxinA and conventional treatment of poststroke arm spasticity: a prospective, non-interventional, open-label, parallel-group study
por: Dressler, Dirk, et al.
Publicado: (2015)

Long‐term fatigue following aneurysmal subarachnoid haemorrhage and the impact on employment
por: Gaastra, Ben, et al.
Publicado: (2022)

Long‐term independence and quality of life after subthalamic stimulation in Parkinson disease
por: Castrioto, Anna, et al.
Publicado: (2022)

Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study
por: Comella, Cynthia, et al.
Publicado: (2022)

Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects
por: Masakado, Yoshihisa, et al.
Publicado: (2022)

Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia: A multicenter, placebo‐controlled, randomized, double‐blinded, parallel‐group comparison/open‐label clinical trial
por: Hyodo, Masamitsu, et al.
Publicado: (2021)

Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease
por: Sauerbier, Anna, et al.
Publicado: (2021)

Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson’s disease
por: Stoker, Thomas B, et al.
Publicado: (2020)

One21: A Novel, Customizable Injection Protocol for Treatment of the Forehead with IncobotulinumtoxinA
por: de Sanctis Pecora, Carla
Publicado: (2020)

Efficacy and safety of non‐ergot dopamine‐receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta‐analysis
por: Chen, Xiang‐Ting, et al.
Publicado: (2022)

Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy
por: Jost, Wolfgang H., et al.
Publicado: (2012)

Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach
por: Aviles-Olmos, Iciar, et al.
Publicado: (2014)

IncobotulinumtoxinA in aesthetics: Russian multidisciplinary expert consensus recommendations
por: Yutskovskaya, Yana, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g3ubalcl8h9ba53fi7k7jpeec3